@article{oai:jrckicn.repo.nii.ac.jp:00000847,
 author = {松石, 雄二朗 and MATSUISHI, Yujiro and SAKURAMOTO, Hideaki and 櫻本, 秀明 and 星野, 晴彦 and HOSHINO, Haruhiko and SIMOJO, Nobutake and 下條, 信威 and 榎本, 有希 and ENOMOTO, Yuki and Mathis, Bryan and 平松, 祐司 and HIRAMATSU, Yuji and 井上, 貴昭 and INOUE, Yoshiaki},
 issue = {1},
 journal = {Scientific Reports},
 month = {Feb},
 note = {application/pdf, Down syndrome (DS) is frequently comorbid with congenital heart disease and has recently been shown to reduce the sedative effect of benzodiazepine (BDZ)-class anesthesia but this effect in a clinical setting has not been studied. Therefore, this study compared midazolam sedation after heart surgery in DS and normal children. We retrospectively reviewed patient records in our pediatric intensive care unit (PICU) of pediatric cardiovascular operations between March 2015 and March 2018. We selected five days of continuous post-operative data just after termination of muscle relaxants. Midazolam sedation was estimated by Bayesian inference for generalized linear mixed models. We enrolled 104 patients (average age 26 weeks) of which 16 (15%) had DS. DS patients had a high probability of receiving a higher midazolam dosage and dexmedetomidine dosage over the study period (probability = 0.99, probability = 0.97) while depth of sedation was not different in DS patients (probability = 0.35). Multi regression modeling included severity scores and demographic data showed DS decreases midazolam sedation compared with controls (posterior OR = 1.32, 95% CrI = 1.01–1.75). In conclusion, midazolam dosages should be carefully adjusted as DS significantly decreases midazolam sedative effect in pediatric heart surgery patients.},
 title = {Down Syndrome Reduces the Sedative Effect of Midazolam in Pediatric Cardiovascular Surgical Patients},
 volume = {10},
 year = {2020},
 yomi = {マツイシ, ユウジロウ and サクラモト, ヒデアキ and ホシノ, ハルヒコ and シモジョウ, ノブタケ and エノモト, ユウキ and ヒラマツ, ユウジ and イノウエ, ヨシアキ}
}